Should short peptides be regulated as small molecules or as biologics?

Susan Finston’s recent post on redefining protein products has raised some debate on the regulatory status of short peptides.

What is your opinion? Should short peptides be regulated as small molecules or as biologics?

Sound off in the comments on Susan’s post.